Neos Therapeutics, Inc.

Robbins LLP Is Investigating the Officers and Directors of Neos Therapeutics, Inc. (NEOS) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Neos Therapeutics, Inc. (NASDAQGM: NEOS) violated federal securities laws in connection with its initial public offering (“IPO”). Neos, a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.

Neos’s Stock Price Falls

On July 23, 2015, Neos held its IPO, selling 4.8 million shares of stock and raising $72 million in new capital. However, since the IPO, Neos’s stock has fallen from its high of $27.09 per share in August 2015 to close at $5.90 per share on October 31, 2016. The decline may be due to the fact that Neos’s business operations and financial prospects were not as strong as represented in the company’s Registration Statement that it filed with the U.S. Securities and Exchange Commission.

Neos Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Skip to content